Allogene Therapeutics, Inc.
ALLONasdaqCIK 1737287HealthcareFiscal year ends Dec 31
Reports and events: 139 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2023-11-0216:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-23-000089 |
| 2023-10-1716:34 ET | 8-K/A | 5.02 Departure or appointment of officers or directors | 0001737287-23-000083 |
| 2023-10-1608:31 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001737287-23-000079 |
| 2023-08-0216:07 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0001737287-23-000076 |
| 2023-08-0216:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-23-000074 |
| 2023-06-2116:05 ET | 8-K | 8.01 Other events | 0001737287-23-000067 |
| 2023-06-1516:08 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001737287-23-000063 |
| 2023-06-1408:04 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001737287-23-000060 |
| 2023-06-0716:16 ET | 8-K | 8.01 Other events | 0001737287-23-000056 |
| 2023-05-0316:09 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0001737287-23-000053 |
| 2023-05-0316:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-23-000051 |
| 2023-04-2416:06 ET | DEF 14A | Proxy statement | 0001737287-23-000041 |
| 2023-04-2016:08 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001737287-23-000028 |
| 2023-03-1016:00 ET | 8-K | 7.01 Regulation FD disclosure | 0001737287-23-000023 |
| 2023-02-2816:12 ET | 10-K | Annual reportPeriod 2022-12-31 | 0001737287-23-000018 |
| 2023-02-2816:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-23-000017 |
| 2023-01-0308:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001737287-23-000003 |
| 2022-11-2915:33 ET | 8-K | 8.01 Other events | 0001737287-22-000089 |
| 2022-11-0216:22 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0001737287-22-000083 |
| 2022-11-0216:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-22-000081 |
| 2022-10-0616:20 ET | 8-K | 8.01 Other events | 0001737287-22-000074 |
| 2022-09-2109:05 ET | 8-K | 8.01 Other events | 0001737287-22-000072 |
| 2022-08-0916:13 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0001737287-22-000067 |
| 2022-08-0916:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-22-000065 |
| 2022-07-1216:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001737287-22-000049 |
| 2022-06-1716:16 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001737287-22-000039 |
| 2022-05-0416:19 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0001737287-22-000035 |
| 2022-05-0416:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-22-000033 |
| 2022-04-2616:28 ET | DEF 14A | Proxy statementPeriod 2022-06-15 | 0001737287-22-000026 |
| 2022-02-2316:11 ET | 10-K | Annual reportPeriod 2021-12-31 | 0001737287-22-000013 |
| 2022-02-2316:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-22-000012 |
| 2022-01-1816:50 ET | SC 13D/A | Ownership report, active investor, amended | 0001387131-22-000412 |
| 2021-12-1510:09 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events | 0001737287-21-000054 |
| 2021-11-0416:20 ET | 10-Q | Quarterly reportPeriod 2021-09-30 | 0001737287-21-000051 |
| 2021-11-0416:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-21-000049 |
| 2021-10-0716:20 ET | 8-K | 8.01 Other events | 0001737287-21-000042 |
| 2021-08-0416:42 ET | 10-Q | Quarterly reportPeriod 2021-06-30 | 0001737287-21-000040 |
| 2021-08-0416:37 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-21-000039 |
| 2021-08-0216:29 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001737287-21-000034 |
| 2021-06-1516:01 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001737287-21-000030 |
| 2021-05-2017:20 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001737287-21-000027 |
| 2021-05-1917:04 ET | 8-K | 8.01 Other events | 0001737287-21-000025 |
| 2021-05-0516:24 ET | 10-Q | Quarterly reportPeriod 2021-03-31 | 0001737287-21-000022 |
| 2021-05-0516:20 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-21-000021 |
| 2021-04-2216:27 ET | DEF 14A | Proxy statementPeriod 2021-06-10 | 0001737287-21-000013 |
| 2021-02-2516:57 ET | 10-K | Annual reportPeriod 2020-12-31 | 0001737287-21-000009 |
| 2021-02-2516:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-21-000007 |
| 2020-12-1508:32 ET | 8-K | 1.01 Entry into a material agreement | 0001737287-20-000064 |
| 2020-12-0708:31 ET | 8-K | 8.01 Other events | 0001737287-20-000061 |
| 2020-11-0408:00 ET | 10-Q | Quarterly reportPeriod 2020-09-30 | 0001737287-20-000059 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 10, 2026, 16:34 ET. Listed shows no prices and gives no investment advice.